Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Giuseppe Basso

Showing results (351-360 of 379) with videos related to

Pageof 38
Sort By:
Blood|February 16, 2010
Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: results in 3184 patients of the AIEOP-BFM ALL 2000 studyValentino Conter, Claus R Bartram, Maria Grazia Valsecchi, et al.
Blood|February 19, 2016
Dexamethasone vs prednisone in induction treatment of pediatric ALL: results of the randomized trial AIEOP-BFM ALL 2000Anja Möricke, Martin Zimmermann, Maria Grazia Valsecchi, et al.
Blood|September 24, 2017
Protocol II vs protocol III given twice during reinduction therapy in children with medium-risk ALLFranco Locatelli, Maria Grazia Valsecchi, Anja Möricke, et al.
Leukemia|December 7, 2019
Randomized post-induction and delayed intensification therapy in high-risk pediatric acute lymphoblastic leukemia: long-term results of the international AIEOP-BFM ALL 2000 trialAndishe Attarbaschi, Georg Mann, Martin Zimmermann, et al.
Lancet (London, England)|September 23, 2008
Mutations of JAK2 in acute lymphoblastic leukaemias associated with Down's syndromeDani Bercovich, Ithamar Ganmore, Linda M Scott, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 18, 2017
Reduced-Intensity Delayed Intensification in Standard-Risk Pediatric Acute Lymphoblastic Leukemia Defined by Undetectable Minimal Residual Disease: Results of an International Randomized Trial (AIEOP-BFM ALL 2000)Martin Schrappe, Kirsten Bleckmann, Martin Zimmermann, et al.
Nature Genetics|October 20, 2009
Rearrangement of CRLF2 in B-progenitor- and Down syndrome-associated acute lymphoblastic leukemiaCharles G Mullighan, J Racquel Collins-Underwood, Letha A A Phillips, et al.
Haematologica|August 5, 2018
Pre-clinical evaluation of second generation PIM inhibitors for the treatment of T-cell acute lymphoblastic leukemia and lymphomaRenate De Smedt, Sofie Peirs, Julie Morscio, et al.
Blood|January 12, 2024
CD371-positive pediatric B-cell acute lymphoblastic leukemia: propensity to lineage switch and slow early response to treatmentBarbara Buldini, Elena Varotto, Margarita Maurer-Granofszky, et al.
Haematologica|October 12, 2019
Relapses and treatment-related events contributed equally to poor prognosis in children with ABL-class fusion positive B-cell acute lymphoblastic leukemia treated according to AIEOP-BFM protocolsGunnar Cario, Veronica Leoni, Valentino Conter, et al.
Pageof 38

Showing results (351-360 of 379) with videos related to

Sort By:
Pageof 38
Blood|February 16, 2010
Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: results in 3184 patients of the AIEOP-BFM ALL 2000 studyValentino Conter, Claus R Bartram, Maria Grazia Valsecchi, et al.
Blood|February 19, 2016
Dexamethasone vs prednisone in induction treatment of pediatric ALL: results of the randomized trial AIEOP-BFM ALL 2000Anja Möricke, Martin Zimmermann, Maria Grazia Valsecchi, et al.
Blood|September 24, 2017
Protocol II vs protocol III given twice during reinduction therapy in children with medium-risk ALLFranco Locatelli, Maria Grazia Valsecchi, Anja Möricke, et al.
Leukemia|December 7, 2019
Randomized post-induction and delayed intensification therapy in high-risk pediatric acute lymphoblastic leukemia: long-term results of the international AIEOP-BFM ALL 2000 trialAndishe Attarbaschi, Georg Mann, Martin Zimmermann, et al.
Lancet (London, England)|September 23, 2008
Mutations of JAK2 in acute lymphoblastic leukaemias associated with Down's syndromeDani Bercovich, Ithamar Ganmore, Linda M Scott, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 18, 2017
Reduced-Intensity Delayed Intensification in Standard-Risk Pediatric Acute Lymphoblastic Leukemia Defined by Undetectable Minimal Residual Disease: Results of an International Randomized Trial (AIEOP-BFM ALL 2000)Martin Schrappe, Kirsten Bleckmann, Martin Zimmermann, et al.
Nature Genetics|October 20, 2009
Rearrangement of CRLF2 in B-progenitor- and Down syndrome-associated acute lymphoblastic leukemiaCharles G Mullighan, J Racquel Collins-Underwood, Letha A A Phillips, et al.
Haematologica|August 5, 2018
Pre-clinical evaluation of second generation PIM inhibitors for the treatment of T-cell acute lymphoblastic leukemia and lymphomaRenate De Smedt, Sofie Peirs, Julie Morscio, et al.
Blood|January 12, 2024
CD371-positive pediatric B-cell acute lymphoblastic leukemia: propensity to lineage switch and slow early response to treatmentBarbara Buldini, Elena Varotto, Margarita Maurer-Granofszky, et al.
Haematologica|October 12, 2019
Relapses and treatment-related events contributed equally to poor prognosis in children with ABL-class fusion positive B-cell acute lymphoblastic leukemia treated according to AIEOP-BFM protocolsGunnar Cario, Veronica Leoni, Valentino Conter, et al.
Pageof 38